Youhong Niu
University of South Florida
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Youhong Niu.
Current Medicinal Chemistry | 2011
Rongsheng E. Wang; Haifan Wu; Youhong Niu; Jianfeng Cai
Ever since the invention of SELEX (systematic evolution of ligands by exponential enrichment), there has been rapid development for aptamers over the last two decades, making them a promising approach in therapeutic applications as either drug candidates or diagnostic tools. For therapeutic purposes, a durable performance of aptamers in biofluids is required, which is, however, hampered by the lack of stability of most aptamers. Not only are the nucleic acid aptamers susceptible to nucleases, the peptide aptamers are also subjective to degradation by proteases. With the advancement of chemical biology, numerous attempts have been made to overcome this obstacle, many resulting in significant improvements in stability. In this review, chemical modifications to increase the stability of three main types of aptamers, DNA, RNA and peptide are comprehensively summarized. For nucleic acid aptamers, development of modified SELEX coupled with mutated polymerase is discussed, which is adaptive to a number of modifications in aptamers and in a large extent facilitates the research of aptamer-modifications. For peptide aptamers, approaches in molecular biology with introduction of stabilizing protein as well as the switch of scaffold protein are included, which may represent a future direction of chemical conjugations to aptamers.
Journal of Medicinal Chemistry | 2012
Youhong Niu; Shruti Padhee; Haifan Wu; Ge Bai; Qiao Qiao; Yaogang Hu; Lacey Harrington; Whittney N. Burda; Lindsey N. Shaw; Chuanhai Cao; Jianfeng Cai
There is increasing demand to develop antimicrobial peptides (AMPs) as next generation antibiotic agents, as they have the potential to circumvent emerging drug resistance against conventional antibiotic treatments. Non-natural antimicrobial peptidomimetics are an ideal example of this, as they have significant potency and in vivo stability. Here we report for the first time the design of lipidated γ-AApeptides as antimicrobial agents. These lipo-γ-AApeptides show potent broad-spectrum activities against fungi and a series of Gram-positive and Gram-negative bacteria, including clinically relevant pathogens that are resistant to most antibiotics. We have analyzed their structure-function relationship and antimicrobial mechanisms using membrane depolarization and fluorescent microscopy assays. Introduction of unsaturated lipid chain significantly decreases hemolytic activity and thereby increases the selectivity. Furthermore, a representative lipo-γ-AApeptide did not induce drug resistance in S. aureus, even after 17 rounds of passaging. These results suggest that the lipo-γ-AApeptides have bactericidal mechanisms analogous to those of AMPs and have strong potential as a new class of novel antibiotic therapeutics.
Chemical Communications | 2011
Youhong Niu; Shruti Padhee; Haifan Wu; Ge Bai; Lacey Harrington; Whittney N. Burda; Lindsey N. Shaw; Chuanhai Cao; Jianfeng Cai
We report the identification of a new class of antimicrobial peptidomimetics-γ-AApeptides with potent and broad-spectrum activity, including clinically-relevant strains that are unresponsive to most antibiotics. They are also not prone to select for drug-resistance.
Journal of Controlled Release | 2012
Rongsheng E. Wang; Frankie Costanza; Youhong Niu; Haifan Wu; Yaogang Hu; Whitney Hang; Yiqun Sun; Jianfeng Cai
Traditional dendrimers possess unique cascade-branched structural properties that allow for multivalent modifications with drug cargos, targeting/delivery agents and imaging tools. In addition to multivalency, the dendrimers macromolecular size also brings about the enhanced permeability and retention (EPR) effect, which makes it an attracting agent for drug delivery and biosensing. Similar to other macromolecules, therapeutic application of dendrimers in the human body faces practical challenges such as target specificity and toxicity. The latter represents a substantial issue due to the dendrimers unnatural chemical structure and relatively large size, which prohibit its in vivo degradation and excretion from the body. To date, a class of self-immolative dendrimers has been developed to overcome these obstacles, which takes advantage of its unique structural backbone to allow for cascade decompositions upon a simple triggering event. The specific drug release can be achieved through a careful design of the trigger, and as a result of the fragmentation, the generated small molecules are either biodegradable or easily excreted from the body. Though still at a preliminary stage, the development of this novel approach represents an important direction in nanoparticle-mediated drug delivery and sensor design, thereby opening up an insightful frontier of dendrimer based applications.
Organic and Biomolecular Chemistry | 2011
Youhong Niu; Alisha “Jonesy” Jones; Haifan Wu; Gabriele Varani; Jianfeng Cai
The interactions between proteins and RNAs are of vital importance for many cellular processes, including transcription and processing of RNA, translation, and viral infections. Here we report an γ-AApeptide that can mimic HIV-1 Tat protein and bind to TAR RNAs of HIV and BIV with nanomolar affinity, comparable to that of the RNA-binding fragment of Tat (amino acids 49-58). The interaction is resistant to the presence of a large excess of tRNA. With resistance to proteolytic hydrolysis and limitless potential for diversification, γ-AApeptides may emerge as a new class of peptidomimetics to modulate RNA-protein interactions.
CrystEngComm | 2012
Wen-Yang Gao; Youhong Niu; Yao Chen; Lukasz Wojtas; Jianfeng Cai; Yu-Sheng Chen; Shengqian Ma
A two-fold interpenetrating microporous metal–organic framework, MMCF-1, has been constructed via the self-assembly of a custom-designed macrocyclic tetracarboxylate ligand and Cd(II), and it exhibits interesting selective uptake of CO2 over N2.
Future Medicinal Chemistry | 2012
Youhong Niu; Rongsheng E. Wang; Haifan Wu; Jianfeng Cai
Antimicrobial peptides (AMPs) hold promise to circumvent the emergence of drug resistance occurring in the treatment of bacteria using many conventional antibiotics. Antimicrobial peptidomimetics, which mimic bactericidal mechanisms of AMPs, may overcome the disadvantages of AMPs and become the new generation of antibiotic therapeutics. In this review, some recent examples in the development of antimicrobial peptidomimetics are highlighted. The potential of antimicrobial agents has been demonstrated for therapeutic uses. Meanwhile, perspectives on their further development and applications are also presented.
Chemical Science | 2012
Haifan Wu; Youhong Niu; Shruti Padhee; Rongsheng E. Wang; Yaqiong Li; Qiao Qiao; Ge Bai; Chuanhai Cao; Jianfeng Cai
Antimicrobial drug resistance is one of the greatest threats facing mankind. Antimicrobial peptides (AMPs) can potentially circumvent drug resistance, probably through a bacterial membrane-disruption mechanism. However, they suffer from low in vivo stability, potential immunogenicity, and difficulty in optimization. The development of antimicrobial peptidomimetics is therefore an emerging research area as they avoid the potential disadvantages of AMPs. Cyclic peptidomimetics are of significant interest since constraints induced by cyclization are expected to further improve their antimicrobial activity. Nonetheless, the report of cyclic oligomeric peptidomimetics for antimicrobial development is rare. Herein, for the first time, we report the design and synthesis of cyclic γ-AApeptides via an on-resin cyclization. These cyclic γ-AApeptides are potent and broad-spectrum active against fungus and multi-drug resistant Gram-positive and Gram-negative bacterial pathogens. Our results demonstrate the potential of cyclic γ-AApeptides as a new class of antibiotics to circumvent drug resistance by mimicking the bactericidal mechanism of AMPs. Meanwhile, the facile synthesis of cyclic γ-AApeptides may further expand the applications of γ-AApeptides in biomedical sciences.
Chemical Communications | 2012
Yunan Yang; Youhong Niu; Hao Hong; Haifan Wu; Yin Zhang; Jonathan W. Engle; Todd E. Barnhart; Jianfeng Cai; Weibo Cai
A γ-AApeptide-based tracer for positron emission tomography imaging of integrin α(v)β(3) is reported. Despite its shorter sequence and linear nature, this tracer had comparable integrin α(v)β(3) binding affinity to the cyclic arginine-glycine-aspartic acid peptide but significantly higher resistance to enzymatic degradation and better stability.
Anti-cancer Agents in Medicinal Chemistry | 2012
Rongsheng E. Wang; Youhong Niu; Haifan Wu; Yaogang Hu; Jianfeng Cai
Besides the common issue of drug-resistance, the conventional approaches for cancer diagnostics and treatment are constantly challenged by poor selectivity and limited access to neoplastic cells, which not only lead to the dose-limiting effect on the tumor region, but also bring side-effects to healthy cells/tissues. In recent years, a novel strategy has arisen to target the vasculature of tumors for drug-delivery and molecular imaging, based on the success of anti-angiogenic therapy. In addition to being easily accessible, the endothelial cells of tumor vasculature are also genetically stable and thus do not develop drug-resistance, making them ideal targets for chemotherapeutics and biomedical imaging. Among various ligands identified so far, the Asn-Gly-Arg (NGR) tripeptide can specifically target the neovasculature via interaction with the aminopeptidase N (APN/CD13) receptor which is highly up-regulated in the membranes of endothelial tumor cells. NGR-directed drug delivery as well as molecular imaging have therefore been undergone development, and appear to be intriguing approaches in current cancer research. Herein we highlight some recent developments of the NGR peptide based cancer therapy including drug-delivery and imaging studies, with future perspectives. Some of these agents have been under clinical trials, indicating promising future for the NGR-based drugs.